|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01801 INNOVENT BIO
Nominal 
111.000 +1.200 (+1.093%) | 2026/06 - Interim RMB(K¥) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 10,001,012 | 1,287,024 | 147,810 | (1,918,804) |
| Net Cash from / (used in) Investing Activities | -- | (6,511,540) | (1,165,411) | (998,662) | (1,435,185) |
| Net Cash from / (used in) Financing Activities | -- | 4,728,470 | (606,632) | 2,587,257 | 2,892,082 |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 8,217,942 | (485,019) | 1,736,405 | (461,907) |
| Cash & Cash Equivalents at beginning of period | -- | 2,273,356 | 2,745,693 | 1,016,165 | 1,359,408 |
| Effect of Foreign Exchange Rate Changes | -- | (115,586) | 12,682 | (6,877) | 118,664 |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 10,375,712 | 2,273,356 | 2,745,693 | 1,016,165 |
| Remarks: | Real time quote last updated: 27/08/2026 09:12 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,253,142 |
| %Change | 50.199% |
| EPS / (LPS) | RMB 0.730 |
| NBV Per Share (¥) | RMB 11.935 |